← Leaderboards
Stephen I Shibata
University Of Southern California
$1,279,059
Attributed
$1,279,059
Total exposure
24
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $380.9K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$1,279,059 · 24
By mechanism
M01$1,279,059 · 24
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Jeffrey Y Wong$938,530
- Jeffrey S Weber$20,866,039
- Laurie D Deleve$11,554,929
- Amrita Krishnan$301,778
- Richard James Cote$13,022,506
Others in their field
Top investigators on “Institution”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,187,810,557
- Leonard Freedman · Leidos Biomedical Research, Inc.$835,530,754
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$566,554,288
- Bambra Strokes · Ppd Development Lp$526,656,217
Research focus
InstitutionGrantClinical ResearchSourceResourcesComputer Retrieval Of Information On Scientific Projects DatabaseFundingResearch PersonnelUnited States National Institutes Of HealthDoseDrug KineticsPharmaceutical PreparationsHuman SubjectSafetyClinical Trial Phase IHuman Therapy EvaluationTumorClinical TrialsNeoplasm /Cancer ChemotherapyMalignant NeoplasmsIntravenous AdministrationDosageChemotherapyBiopsy
Grant awards (34)
PHI-56: NCI #6813: A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMS$107,832
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHI-59: PHASE I AND PHARMAKOKINETIC STUDY OF VORINOSTAT$39,421
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PHASE 1 AND PHARMACOKINETIC SINGLE AGENT STUDY OF PAZOPANIB ADVA$20,871
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: NCI #5874, PHI-43: "A PHASE I PHARMACOKINETIC STUDY OF PS341 IN$16,234
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PHASE I PHARMACOKINETIC STUDY OF PS-341 IN PATIENTS WITH ADVAN$10,435
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: PILOT PHARMACOKINETIC STUDY OF DOSE ADJUSTMENT OF VINORELBINE IN$2,320
M01 · FY2009 · RR · contact PI
PHI-56: NCI #6813: A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMS$267,986
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: PILOT PHARMACOKINETIC STUDY OF DOSE ADJUSTMENT OF VINORELBINE IN$51,673
M01 · FY2008 · RR · contact PI
A PHASE I PHARMACOKINETIC STUDY OF PS-341 IN PATIENTS WITH ADVANCED$44,463
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: NCI #5874, PHI-43: "A PHASE I PHARMACOKINETIC STUDY OF PS341 IN$16,826
M01 · FY2008 · RR · contact PI
PILOT PHARMACOKINETIC STUDY OF DOSE ADJUSTMENT OF VINORELBINE IN PATIENTS WITH V$45,549
M01 · FY2007 · RR · contact PI
PHI-56: NCI #6813: A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMS$21,320
M01 · FY2007 · RR · contact PI
A PHASE I STUDY OF A COMBINATION OF YTTRIUM-90 LABELED ANTI-CEA ANTIBODY$10,661
M01 · FY2007 · RR · contact PI
PHI-35: A PHASE I STUDY OF THE TOXICITIES, BIOLOGIC AND CLINICAL EFFECTS OF DAIL$1,939
M01 · FY2007 · RR · contact PI
A PHASE I PHARMACOKINETIC STUDY OF PS-341 IN PATIENTS WITH ADVANCED$1,939
M01 · FY2007 · RR · contact PI
A PHASE I STUDY OF A COMBINATION OF YTTRIUM-90 LABELED ANTI-CEA ANTIBODY$37,014
M01 · FY2006 · RR · contact PI
PILOT PHARMACOKINETIC STUDY OF DOSE ADJUSTMENT OF VINORELBINE IN PATIENTS WITH$14,152
M01 · FY2006 · RR · contact PI
NCI #5874, PHI-43: "A PHASE I PHARMACOKINETIC STUDY OF PS341 IN PATIENTS WITH$1,088
M01 · FY2006 · RR · contact PI
PILOT PHARMACOKINETIC STUDY OF DOSE ADJUSTMENT OF VINORELBINE IN PATIENTS WITH V$52,681
M01 · FY2005 · RR
PHI-35: A PHASE I STUDY OF THE TOXICITIES, BIOLOGIC AND CLINICAL EFFECTS OF DAIL$49,582
M01 · FY2005 · RR
A PHASE I STUDY OF A COMBINATION OF YTTRIUM-90 LABELED ANTI-CEA ANTIBODY$35,120
M01 · FY2005 · RR
NCI #5874, PHI-43: "A PHASE I PHARMACOKINETIC STUDY OF PS341 IN PATIENTS WITH A$34,088
M01 · FY2005 · RR
A PHASE I PHARMACOKINETIC STUDY OF STI-571 IN PATIENTS WITH ADVANCED MALIGNANCI$17,716
M01 · FY2005 · RR
A PHASE I PHARMACOKINETIC STUDY OF STI-571 IN PATIENTS WITH ADVANCED MALIGNANCI$2,067
M01 · FY2005 · RR
PHASE 1 STUDY OF CIS-DIAMMINEDICHLOROPLATINUM IN COMBINATION WITH ICRF-187 IN$1,032
M01 · FY2005 · RR
A Phase I Study of a Combination of Yttrium-90 Labeled$127,946
M01 · FY2004 · RR
Phase 1 Study of Cis-Diamminedichloroplatinum$28,884
M01 · FY2004 · RR
Pharmacokinetic Study of Dose Adjustment of Vinorelbine$23,694
M01 · FY2004 · RR
PHI-35: A Phase I Study of Toxic &Biologic Effects$3,209
M01 · FY2004 · RR
5 ASA 2 DEOXYCYTIDINE (DAC) IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2002 · RR
5 ASA 2 DEOXYCYTIDINE (DAC) IN PATIENTS W/ ADVANCED MALIGNANCIES$155,764
M01 · FY2001 · RR
5 ASA 2 DEOXYCYTIDINE (DAC) IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2001 · RR
5 ASA 2 DEOXYCYTIDINE (DAC) IN PATIENTS W/ ADVANCED MALIGNANCIES$35,553
M01 · FY2000 · RR
5 ASA 2 DEOXYCYTIDINE (DAC) IN PATIENTS W/ ADVANCED MALIGNANCIES$0
M01 · FY2000 · RR